Hou Jiangxue, Li Yufu, Lin Quande
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Exp Hematol Oncol. 2023 Aug 26;12(1):74. doi: 10.1186/s40164-023-00436-9.
Bispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses. Here, we summarize the latest data from the 2023 ASCO annual meeting on BsAbs targeting BCMA/CD3, GPRC5D/CD3 and BCMA/CD19 CAR T cells.
在过去几年中，双特异性抗体（BsAbs）和双靶点嵌合抗原受体T（CAR T）细胞已被应用于复发/难治性多发性骨髓瘤（RRMM）患者，因为越来越多的患者在接受≥3线既往治疗后疗效不佳。BCMA/CD3和GPRC5D/CD3是最常用的组合。临床研究结果表明，患者对更强、更持久的反应表现出更高的敏感性。在此，我们总结了2023年美国临床肿瘤学会（ASCO）年会关于靶向BCMA/CD3、GPRC5D/CD3的BsAbs以及BCMA/CD19 CAR T细胞的最新数据。
